ClinicalTrials.gg
CompletedNCT02714569Updated May 25, 2021Results posted

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

A Phase 1 interventional study of LY3202328 and Placebo in Dyslipidemias, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
37th of 47
60 · median 165
Started
2016
the only one that year
Phase 1
3 of 47
none open now
Registered
35th of 47
by date
Lead sponsor
3 of 47
Eli Lilly and Company

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 37th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 1, and was the 35th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be healthy, as determined by medical history and physical examination
  • Male participants must be between 18 and 70 years of age and must agree to use a reliable method of during the study and 3 months following the last dose of the product
  • Female participants must be between 40 and 70 years old, and either or with a hysterectomy, and not pregnant and not lactating
  • Be on a stable diet and exercise regimen for greater than (>) 3 months prior
  • Have a (BMI) of 25.0 to 35.0 (Part A) or 27.0 to 40.0 (Part B) kilograms per meter squared
  • Have fasting triglycerides (TG) between 150 and 499 milligrams per deciliter (mg/dL) (Part B only)
  • Have a fasting low-density lipoprotein cholesterol (LDL-c) between 100 and 200 mg/dL (Part B only)
  • Have estimated greater than or equal to (≥) 60 milliliters per minute/1.73 meter squared with no proteinuria
  • Be normotensive defined as supine systolic blood pressure (BP) less than or equal to (≤) 150 millimeters of mercury (mm Hg) and diastolic BP ≤ 100 mm Hg, without the use of any antihypertensive

Exclusion criteria

Exclusion Criteria:

  • Are taking a statin, any proprotein convertase subtilisin/kexin type 9 (PCSK9) medications, or have started taking other TG lowering agents (for example, niacin, fish oils)
  • Are currently enrolled in a clinical trial involving an product or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research, or have participated in a clinical trial involving an investigational product or non-approved use of a drug within the last 30 days or within 5 half-lives
  • Have an abnormal or or are on antihypertensive treatment
  • Have any current or prior history of significant cardiovascular disease
  • Show evidence of virus (HCV), or other chronic liver disease
  • Have an alcohol intake that exceeds 7 units per week with no more than 3 units per day, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of distilled spirits), or are a regular user of known drugs of abuse
  • Have a history of untreated endocrine illness such as diabetes mellitus
  • Have been on medications or supplements for weight loss within 3 months
  • Have a history of active neuropsychiatric disease or on pharmacological therapy for such conditions (Part B, only)
  • Show evidence of (HIV) infection
  • Have been on medications that are known to inhibit cytochrome P450, family 3, subfamily A () or P-glycoprotein (P-gp), or regularly consume grapefruit
  • Have donated blood of more than 500 mL within the last month
  • Smoke >10 cigarettes per day or are unwilling to follow smoking rules
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Part A: LY3202328 (LY)

    Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.

    Drug: LY3202328

  • Placebo comparator
    Part A: Placebo

    A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.

    Drug: Placebo

  • Experimental
    Part B: LY3202328 (LY)

    A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.

    Drug: LY3202328 · Drug: Atorvastatin · Drug: Simvastatin

  • Placebo comparator
    Part B: Placebo

    A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.

    Drug: Placebo · Drug: Atorvastatin · Drug: Simvastatin

Interventions

  • DrugLY3202328

    Administered orally

  • DrugPlacebo

    Administered orally

  • Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B

    Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

    Time frame: Baseline, Up to 42 Days

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose

    Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose

  2. PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B

    PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.

    Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  3. PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose

    PK is the area under the serum concentration time curve from zero to Infinity (AUC\[0-∞\]) of LY3202328 in Part A after a single dose.

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose

  4. PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B

    PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.

    Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  5. PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A

    PK is the time to maximum concentration (Tmax) of LY3202328 in Part A

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose

  6. PK: Steady State Tmax of LY3202328 (LY) in Part B

    PK is the Tmax of LY3202328 at steady state in Part B.

    Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  7. Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A

    Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.

    Time frame: Predose, 24, 48, 96 Hours Postdose

  8. PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B

    PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.

    Time frame: Predose, Days 7, 14, 21, and 28 Postdose

  9. PD: Change From Baseline in Fasting Total Triglycerides Part A

    PD is the change from baseline in fasting total triglycerides in Part A.

    Time frame: Predose, 24, 48, 96 Hours Postdose

  10. PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B

    PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.

    Time frame: Predose, Days 7, 14, 21, and 28 Postdose

  11. PD: Change From Baseline to in Fasting Total Cholesterol in Part A

    PD is the change from baseline in fasting total cholesterol in Part A.

    Time frame: Predose, 24, 28, 96 Hours Postdose

  12. PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B

    PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.

    Time frame: Predose, Days 7, 14, 21, and 28 Postdose

  13. PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A

    PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.

    Time frame: Predose, 24, 48, 96 Hours Postdose

  14. PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B

    PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.

    Time frame: Predose, Days 7, 14, 21, and 28 Postdose

  15. PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B

    PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.

    Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  16. PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B

    PK: Area Under Concentration Curve From Zero to Time (AUC \[0-t\]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.

    Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  17. PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B

    PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.

    Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

  18. PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B

    PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.

    Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose

07

Results

Posted May 25, 2021

Participant flow

Part A First Intervention
Participant flow — Part A First Intervention
MilestonePart A: Cohort 1(C1), Sequence 1Part A: C1, Sequence 2Part A: C1, Sequence 3Part A: Cohort 2 (C2), Sequence 1Part A: C2, Sequence 2Part A: C2, Sequence 3Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)Part B: C4 (SS/AS + 20 mg LY)Part B: C5 (SS/AS + 100 mg LY)Part B: C6 (SS/AS + 300 mg LY)Part B: C3-C6 (SS/AS + Placebo)
Started33333300000
Received at least one dose of study drug33333300000
Completed33333300000
Not completed00000000000
Part A Second Intervention
Participant flow — Part A Second Intervention
MilestonePart A: Cohort 1(C1), Sequence 1Part A: C1, Sequence 2Part A: C1, Sequence 3Part A: Cohort 2 (C2), Sequence 1Part A: C2, Sequence 2Part A: C2, Sequence 3Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)Part B: C4 (SS/AS + 20 mg LY)Part B: C5 (SS/AS + 100 mg LY)Part B: C6 (SS/AS + 300 mg LY)Part B: C3-C6 (SS/AS + Placebo)
Started33333300000
Received at least one dose of study drug32333300000
Completed32333300000
Not completed01000000000
Withdrew: Withdrawal by subject01000000000
Part A Third Intervention
Participant flow — Part A Third Intervention
MilestonePart A: Cohort 1(C1), Sequence 1Part A: C1, Sequence 2Part A: C1, Sequence 3Part A: Cohort 2 (C2), Sequence 1Part A: C2, Sequence 2Part A: C2, Sequence 3Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)Part B: C4 (SS/AS + 20 mg LY)Part B: C5 (SS/AS + 100 mg LY)Part B: C6 (SS/AS + 300 mg LY)Part B: C3-C6 (SS/AS + Placebo)
Started32333300000
Received at least one dose of study drug32223300000
Completed32223300000
Not completed00110000000
Withdrew: Positive urine drug screen (uds)00010000000
Withdrew: Adverse event00100000000
Part A Fourth Intervention
Participant flow — Part A Fourth Intervention
MilestonePart A: Cohort 1(C1), Sequence 1Part A: C1, Sequence 2Part A: C1, Sequence 3Part A: Cohort 2 (C2), Sequence 1Part A: C2, Sequence 2Part A: C2, Sequence 3Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)Part B: C4 (SS/AS + 20 mg LY)Part B: C5 (SS/AS + 100 mg LY)Part B: C6 (SS/AS + 300 mg LY)Part B: C3-C6 (SS/AS + Placebo)
Started42323300000
Received at least one dose of study drug32323200000
Completed32323200000
Not completed10000100000
Withdrew: Positive urinary drug screen (uds)10000100000
Part B (Overall)
Participant flow — Part B (Overall)
MilestonePart A: Cohort 1(C1), Sequence 1Part A: C1, Sequence 2Part A: C1, Sequence 3Part A: Cohort 2 (C2), Sequence 1Part A: C2, Sequence 2Part A: C2, Sequence 3Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)Part B: C4 (SS/AS + 20 mg LY)Part B: C5 (SS/AS + 100 mg LY)Part B: C6 (SS/AS + 300 mg LY)Part B: C3-C6 (SS/AS + Placebo)
Started00000088888
Completed00000077868
Not completed00000011020
Withdrew: Lost to follow-up00000010000
Withdrew: Withdrawal by subject00000001010
Withdrew: Adverse event00000000010

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B

Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.

Time frame:
Baseline, Up to 42 Days
Reported as:
Number · participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B
participantsPart A: PlaceboPart A: 1 mg LY3202328 (LY)Part A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 30 mg LY FedPart A: 600 mg LYPart B: SS/AS/PlaceboPart B: SS/AS/5 mg of LYPart B: SS/AS/20 mg of LYPart B: SS/AS/100 mg of LYPart B: SS/AS/300 mg of LY
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B00000000000001
SecondaryPharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose

Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose
nanogram/milliliter (ng/mL)Part A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LYPart A: 30 mg LY Fed
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose48.258 ± 21.11105.023 ± 26.66340.829 ± 28.99581.782 ± 32.291600.953 ± 40.011632.595 ± 42.842866.855 ± 51.291105.999 ± 18.47
Statistical analysis
  • Part A: 30 mg LY vs Part A: 30 mg LY Fed · Least square means percentage: 204.8 · 90% CI 161.9 to 259.0Analysis was the estimate of the ratio fasted versus fed.
SecondaryPK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B

PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.

Time frame:
Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · ng/ml
PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B
ng/mlPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B445.858 ± 32.78882.125 ± 32.813687.167 ± 34.833209.396 ± 37.31
SecondaryPK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose

PK is the area under the serum concentration time curve from zero to Infinity (AUC\[0-∞\]) of LY3202328 in Part A after a single dose.

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
Reported as:
Geometric mean · ng/mL
PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose
ng/mLPart A: 1 mg LYPart A: 3 mg of LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg of LYPart A: 300 mg LYPart A: 600 mg LYPart A: 30 mg LY Fed
PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single DoseNA ± NANA ± NA7726.17 ± 45.2317018.43 ± 62.6055406.24 ± 41.3566185.70 ± 71.44NA ± NA28415.22 ± 56.67
Statistical analysis
  • Part A: 30 mg LY vs Part A: 30 mg LY Fed · Least squares mean percentage: 193.3 · 90% CI 144.7 to 258.2
SecondaryPK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B

PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.

Time frame:
Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · hour*nanogram/milliliter(hr*ng/ml)
PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B
hour*nanogram/milliliter(hr*ng/ml)Part B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B7587.24 ± 38.61213362.44 ± 44.98467499.80 ± 37.46550774.85 ± 43.861
SecondaryPK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A

PK is the time to maximum concentration (Tmax) of LY3202328 in Part A

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
Reported as:
Median · hour (hr)
PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A
hour (hr)Part A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LYPart A: 30 mg LY Fed
PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A2.02 (1.0 to 4.0)3.52 (2.0 to 6.2)4.0 (2.0 to 6.0)4.00 (3.0 to 4.1)6.00 (2.0 to 8.0)4.02 (3.0 to 8.0)4.00 (2.0 to 24.0)5.00 (4.0 to 8.0)
SecondaryPK: Steady State Tmax of LY3202328 (LY) in Part B

PK is the Tmax of LY3202328 at steady state in Part B.

Time frame:
Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Median · hr
PK: Steady State Tmax of LY3202328 (LY) in Part B
hrPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PK: Steady State Tmax of LY3202328 (LY) in Part B2.00 (2.0 to 6.0)4.20 (4.0 to 6.0)3.00 (2.0 to 4.0)3.04 (1.0 to 6.0)
SecondaryPharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A

Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.

Time frame:
Predose, 24, 48, 96 Hours Postdose
Reported as:
Mean · millimole/Liter (mmol/L)
Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A
millimole/Liter (mmol/L)Part A: PlaceboPart A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LY
24 Hours-0.003 ± 0.1155-0.030 ± 0.0842-0.043 ± 0.0454-0.047 ± 0.0740-0.026 ± 0.04330.052 ± 0.1099-0.004 ± 0.06840.010 ± 0.0232
48 Hours-0.037 ± 0.1560-0.039 ± 0.02170.009 ± 0.1387-0.043 ± 0.0950-0.026 ± 0.10100.019 ± 0.0978-0.009 ± 0.1551-0.052 ± 0.0755
96 Hours-0.074 ± 0.1258-0.073 ± 0.1241-0.086 ± 0.0892-0.134 ± 0.0553-0.030 ± 0.1304-0.091 ± 0.1206-0.082 ± 0.1487-0.005 ± 0.1411
SecondaryPD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B

PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.

Time frame:
Predose, Days 7, 14, 21, and 28 Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B
mmol/LPart B: PlaceboPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B0.008 ± 0.1169-0.010 ± 0.1165-0.101 ± 0.0812-0.107 ± 0.1894-0.101 ± 0.0621
SecondaryPD: Change From Baseline in Fasting Total Triglycerides Part A

PD is the change from baseline in fasting total triglycerides in Part A.

Time frame:
Predose, 24, 48, 96 Hours Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline in Fasting Total Triglycerides Part A
mmol/LPart A: PlaceboPart A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LY
24 Hours-0.276 ± 0.2043-0.397 ± 0.2877-0.190 ± 0.1491-0.386 ± 0.2766-0.311 ± 0.2831-0.523 ± 0.5801-0.064 ± 0.1455-0.302 ± 0.2318
48 Hours-0.320 ± 0.3162-0.269 ± 0.2260-0.115 ± 0.2643-0.260 ± 0.3382-0.418 ± 0.3290-0.766 ± 0.5870-0.226 ± 0.3646-0.198 ± 0.1345
96 Hours-0.239 ± 0.3227-0.209 ± 0.6817-0.132 ± 0.23490.013 ± 0.7179-0.331 ± 0.4343-0.455 ± 0.5144-0.326 ± 0.35490.158 ± 0.6773
SecondaryPD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B

PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.

Time frame:
Predose, Days 7, 14, 21, and 28 Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B
mmol/LPart B: PlaceboPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B0.205 ± 0.6757-0.131 ± 0.2720-0.231 ± 0.53830.020 ± 0.6281-0.480 ± 0.5235
SecondaryPD: Change From Baseline to in Fasting Total Cholesterol in Part A

PD is the change from baseline in fasting total cholesterol in Part A.

Time frame:
Predose, 24, 28, 96 Hours Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline to in Fasting Total Cholesterol in Part A
mmol/LPart A: PlaceboPart A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LY
24 Hours0.085 ± 0.3075-0.186 ± 0.2699-0.013 ± 0.2850-0.203 ± 0.21570.073 ± 0.18630.285 ± 0.19030.203 ± 0.24210.093 ± 0.1560
48 Hours-0.085 ± 0.4618-0.436 ± 0.2608-0.030 ± 0.2218-0.376 ± 0.2321-0.013 ± 0.39810.091 ± 0.36540.134 ± 0.5446-0.026 ± 0.4719
96 Hours-0.318 ± 0.4288-0.527 ± 0.3262-0.207 ± 0.2949-0.609 ± 0.2635-0.199 ± 0.4732-0.317 ± 0.6296-0.155 ± 0.4826-0.041 ± 0.6020
SecondaryPD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B

PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.

Time frame:
Predose, Days 7, 14, 21, and 28 Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B
mmol/LPart B: PlaceboPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B0.206 ± 0.36150.118 ± 0.38400.183 ± 0.46810.174 ± 0.4963-0.190 ± 0.4425
SecondaryPD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A

PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.

Time frame:
Predose, 24, 48, 96 Hours Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A
mmol/LPart A: PlaceboPart A: 1 mg LYPart A: 3 mg LYPart A: 10 mg LYPart A: 30 mg LYPart A: 100 mg LYPart A: 300 mg LYPart A: 600 mg LY
24 Hours0.231 ± 0.25130.025 ± 0.22050.117 ± 0.24000.020 ± 0.23280.241 ± 0.15940.471 ± 0.34180.236 ± 0.24290.163 ± 0.1608
48 Hours0.111 ± 0.4026-0.275 ± 0.30040.013 ± 0.2093-0.214 ± 0.23780.203 ± 0.34000.419 ± 0.32930.245 ± 0.3457-0.001 ± 0.3891
96 Hours-0.109 ± 0.4147-0.358 ± 0.4170-0.061 ± 0.1747-0.481 ± 0.3681-0.018 ± 0.3048-0.020 ± 0.63270.075 ± 0.25650.038 ± 0.6305
SecondaryPD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B

PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.

Time frame:
Predose, Days 7, 14, 21, and 28 Postdose
Reported as:
Mean · mmol/L
PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B
mmol/LPart B: PlaceboPart B: 5 mg LYPart B: 20 mg LYPart B: 100 mg LYPart B: 300 mg LY
PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B0.103 ± 0.41140.184 ± 0.34190.388 ± 0.48760.227 ± 0.44940.131 ± 0.4225
SecondaryPK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B

PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.

Time frame:
Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B
ng/mlSimvastatin With LY (Test)Simvastatin Alone (Reference)
Placebo2.906 ± 18.722.061 ± 71.24
5 mg LY2.388 ± 58.173.374 ± 52.99
20 mg LY3.576 ± 19.353.274 ± 26.87
100 mg LY4.634 ± 55.594.303 ± 25.45
300 mg LY4.221 ± 58.781.979 ± 55.84
Statistical analysis
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least square means ratio (%): 141.0 · 90% CI 67.9 to 293.0
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least square means ratio (%): 70.8 · 90% CI 31.9 to 157.1
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least square means ratio (%): 109.2 · 90% CI 99.8 to 119.5
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least square means ratio (%): 107.7 · 90% CI 68.1 to 170.4
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 213.3 · 90% CI 200.3 to 227.1
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least square means ratio (%): 115.4 · 90% CI 91.2 to 146.2
SecondaryPK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B

PK: Area Under Concentration Curve From Zero to Time (AUC \[0-t\]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.

Time frame:
Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · hr*ng/ml
PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B
hr*ng/mlSimvastatin With LY (Test)Simvastatin Alone (Reference)
Placebo9.648 ± 38.826.250 ± 61.54
5 mg LY6.668 ± 42.969.287 ± 57.54
20 mg LY9.697 ± 26.817.960 ± 32.21
100 mg LY14.269 ± 53.7810.434 ± 26.20
300 mg LY11.908 ± 60.198.951 ± 61.65
Statistical analysis
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 155 · 90% CI 87.6 to 274.2
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 71.5 · 90% CI 40.7 to 125.3
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratios (%): 122.4 · 90% CI 90.7 to 165.1
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 136.6 · 90% CI 89.8 to 207.7
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 132.6 · 90% CI 90.5 to 194.4
  • Simvastatin With LY (Test) vs Simvastatin Alone (Reference) · Geometric least squares mean ratio (%): 112.2 · 90% CI 93.2 to 135.1
SecondaryPK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B

PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.

Time frame:
Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B
ng/mLAtorvastatin With LY (Test)Atorvastatin Alone (Reference)
Placebo3.479 ± 20.583.575 ± 30.44
5 mg LY2.840 ± 27.963.621 ± 82.05
20 mg LY1.238 ± 38.051.286 ± 45.27
100 mg LY2.511 ± 32.173.105 ± 51.95
300 mg LY1.489 ± 42.111.376 ± 59.68
Statistical analysis
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 97.3 · 90% CI 80.4 to 117.8
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 57.5 · 90% CI 31.3 to 106.0
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 96.2 · 90% CI 66.8 to 138.7
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 80.9 · 90% CI 45.8 to 142.7
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 108.2 · 90% CI 40.2 to 291.2
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 87.9 · 90% CI 67.4 to 114.7
SecondaryPK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B

PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.

Time frame:
Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Reported as:
Geometric mean · hr*ng/ml
PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B
hr*ng/mlAtorvastatin With LY (Test)Atorvastatin Alone (Reference)
Placebo15.874 ± 32.8116.518 ± 33.88
5 mg LY17.311 ± 6.3514.913 ± 48.97
20 mg LY7.921 ± 57.947.952 ± 63.04
100 mg LY11.983 ± 38.6313.207 ± 61.25
300 mg LY7.748 ± 50.049.111 ± 36.39
Statistical analysis
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least square means ratio (%): 96.0 · 90% CI 90.2 to 102.1
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 90.7 · 90% CI 59.8 to 137.6
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least square means ratio (%): 99.9 · 90% CI 75.9 to 131.5
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least square means ratio (%): 91.0 · 90% CI 67.5 to 122.7
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 87.0 · 90% CI 42.0 to 180.5
  • Atorvastatin With LY (Test) vs Atorvastatin Alone (Reference) · Geometric least squares mean ratio (%): 93.5 · 90% CI 81.8 to 106.9

Adverse events

Collected over From Baseline to End of Study (Up to 10 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/25 (0%)0/25 (0%)2/25 (8%)
1 mg LY3202328 (LY)0/6 (0%)0/6 (0%)0/6 (0%)
3 mg LY0/6 (0%)0/6 (0%)0/6 (0%)
5 mg LY0/8 (0%)0/8 (0%)5/8 (62.5%)
10 mg LY0/6 (0%)0/6 (0%)2/6 (33.3%)
20 mg LY0/8 (0%)0/8 (0%)5/8 (62.5%)
30 mg LY0/6 (0%)0/6 (0%)1/6 (16.7%)
30 mg LY Fed0/4 (0%)0/4 (0%)0/4 (0%)
100 mg LY0/12 (0%)0/12 (0%)1/12 (8.3%)
300 mg LY0/14 (0%)2/14 (14.3%)6/14 (42.9%)
600 mg of LY0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo1 mg LY3202328 (LY)3 mg LY5 mg LY10 mg LY20 mg LY30 mg LY30 mg LY Fed100 mg LY300 mg LY600 mg of LY
Alanine aminotransferase increasedInvestigations0/250/60/60/80/60/80/60/40/121/140/5
Aspartate aminotransferase increasedInvestigations0/250/60/60/80/60/80/60/40/121/140/5
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlacebo1 mg LY3202328 (LY)3 mg LY5 mg LY10 mg LY20 mg LY30 mg LY30 mg LY Fed100 mg LY300 mg LY600 mg of LY
HeadacheNervous system disorders1/250/60/62/81/62/80/60/41/122/140/5
Pr interval prolongedInvestigations0/250/60/60/81/60/80/60/40/120/140/5
PapuleSkin and subcutaneous tissue disorders0/250/60/60/80/60/81/60/40/120/140/5
DiarrheaGastrointestinal disorders0/250/60/60/80/61/80/60/40/120/140/5
FlatulenceGastrointestinal disorders0/250/60/61/80/60/80/60/40/120/140/5
NauseaGastrointestinal disorders0/250/60/60/80/61/80/60/40/121/140/5
FatigueGeneral disorders0/250/60/61/80/60/80/60/40/120/140/5
Kidney infectionInfections and infestations0/250/60/60/80/61/80/60/40/120/140/5
Pain in hipMusculoskeletal and connective tissue disorders0/250/60/60/80/61/80/60/40/120/140/5
Stiff neckMusculoskeletal and connective tissue disorders0/250/60/61/80/61/80/60/40/120/140/5

Baseline characteristics

All participants who received at least one dose of study drug in Part A and Part B.

Age, Continuous
Age, Continuous(years)Part A, C1, Sequence 1Part A, C1, Sequence 2Part A, C1, Sequence 3Part A, C2, Sequence 1Part A, C2, Sequence 2Part A, C2, Sequence 3Part B: SS/AS/PlaceboPart B: SS/AS/5 mg LYPart B: SS/AS/20 mg LYPart B: SS/AS/100 mg LYPart B: SS/AS/300 mg LYTotal
Mean48.3 ± 8.0256.0 ± 12.1258.5 ± 4.0434.0 ± 13.5338.3 ± 22.5054.7 ± 17.2154.0 ± 9.1250.5 ± 12.7646.8 ± 13.1355.0 ± 10.1836.9 ± 10.8048.7 ± 13.22
Sex: Female, Male
Sex: Female, Male(Participants)Part A, C1, Sequence 1Part A, C1, Sequence 2Part A, C1, Sequence 3Part A, C2, Sequence 1Part A, C2, Sequence 2Part A, C2, Sequence 3Part B: SS/AS/PlaceboPart B: SS/AS/5 mg LYPart B: SS/AS/20 mg LYPart B: SS/AS/100 mg LYPart B: SS/AS/300 mg LYTotal
Female1120014434121
Male3223324454739
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A, C1, Sequence 1Part A, C1, Sequence 2Part A, C1, Sequence 3Part A, C2, Sequence 1Part A, C2, Sequence 2Part A, C2, Sequence 3Part B: SS/AS/PlaceboPart B: SS/AS/5 mg LYPart B: SS/AS/20 mg LYPart B: SS/AS/100 mg LYPart B: SS/AS/300 mg LYTotal
Hispanic or Latino0001005007215
Not Hispanic or Latino4342333881645
Unknown or Not Reported000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A, C1, Sequence 1Part A, C1, Sequence 2Part A, C1, Sequence 3Part A, C2, Sequence 1Part A, C2, Sequence 2Part A, C2, Sequence 3Part B: SS/AS/PlaceboPart B: SS/AS/5 mg LYPart B: SS/AS/20 mg LYPart B: SS/AS/100 mg LYPart B: SS/AS/300 mg LYTotal
American Indian or Alaska Native000000000000
Asian000000000000
Native Hawaiian or Other Pacific Islander000000000000
Black or African American2113211200013
White2230127688847
More than one race000000000000
Unknown or Not Reported000000000000
Region of Enrollment
Region of Enrollment(Participants)Part A, C1, Sequence 1Part A, C1, Sequence 2Part A, C1, Sequence 3Part A, C2, Sequence 1Part A, C2, Sequence 2Part A, C2, Sequence 3Part B: SS/AS/PlaceboPart B: SS/AS/5 mg LYPart B: SS/AS/20 mg LYPart B: SS/AS/100 mg LYPart B: SS/AS/300 mg LYTotal
United States4343338888860
08

Study locations

4 sites
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
  • PRA Health Sciences
    Lenexa, Kansas 06219, United States
  • PRA Health Sciences
    Marlton, New Jersey 08053, United States
  • PRA Health Sciences
    Salt Lake City, Utah 84106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2016
First posted
Mar 21, 2016
Start
Mar 2016
Primary completionActual
Feb 15, 2017
CompletionActual
Feb 15, 2017
Results first posted
May 25, 2021
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02714569
Responsible party
Sponsor
First posted
Mar 21, 2016
Start date
Mar 2016
Primary completion
Feb 15, 2017
Completion
Feb 15, 2017
Results posted
May 25, 2021
Last update
May 25, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Simvastatin

Start the discussion